company background image
ACL

Australian Clinical LabsASX:ACL Stock Report

Market Cap

AU$865.9m

7D

-1.8%

1Y

n/a

Updated

22 Oct, 2021

Data

Company Financials +
ACL fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health2/6
Dividends0/6

ACL Overview

Australian Clinical Labs Limited provides pathology services.

Australian Clinical Labs Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Australian Clinical Labs
Historical stock prices
Current Share PriceAU$4.29
52 Week HighAU$3.18
52 Week LowAU$5.08
Beta0
1 Month Change-6.54%
3 Month Change14.71%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO25.44%

Recent News & Updates

Sep 01
The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Australian Clinical Labs Limited ( ASX:ACL ) just reported healthy earnings but the stock price didn't move much. Our...

Shareholder Returns

ACLAU HealthcareAU Market
7D-1.8%1.1%0.7%
1Yn/a13.1%21.4%

Return vs Industry: Insufficient data to determine how ACL performed against the Australian Healthcare industry.

Return vs Market: Insufficient data to determine how ACL performed against the Australian Market.

Price Volatility

Is ACL's price volatile compared to industry and market?
ACL volatility
ACL Beta0
Industry Beta0.60
Market Beta1

Stable Share Price: ACL is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: Insufficient data to determine ACL's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20202,794Melinda McGrathhttps://www.clinicallabs.com.au

Australian Clinical Labs Limited provides pathology services. The company offers various routine pathology tests, advanced pathology, first trimester screening and non-invasive prenatal testing, chemical pathology, hematology, histopathology, immunology, serology and microbiology, functional pathology, and commercial drug and alcohol testing services. The company offers its service to private and public hospitals.

Australian Clinical Labs Fundamentals Summary

How do Australian Clinical Labs's earnings and revenue compare to its market cap?
ACL fundamental statistics
Market CapAU$865.87m
Earnings (TTM)AU$60.37m
Revenue (TTM)AU$646.70m

14.3x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACL income statement (TTM)
RevenueAU$646.70m
Cost of RevenueAU$126.47m
Gross ProfitAU$520.23m
ExpensesAU$459.86m
EarningsAU$60.37m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Feb 24, 2022

Earnings per share (EPS)0.30
Gross Margin80.44%
Net Profit Margin9.34%
Debt/Equity Ratio121.3%

How did ACL perform over the long term?

See historical performance and comparison

Valuation

Is Australian Clinical Labs undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ACL (A$4.29) is trading below our estimate of fair value (A$35.65)

Significantly Below Fair Value: ACL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ACL is good value based on its PE Ratio (14.3x) compared to the Australian Healthcare industry average (24.7x).

PE vs Market: ACL is good value based on its PE Ratio (14.3x) compared to the Australian market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: ACL's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: ACL is overvalued based on its PB Ratio (10.6x) compared to the AU Healthcare industry average (2.2x).


Future Growth

How is Australian Clinical Labs forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-15.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACL's earnings are forecast to decline over the next 3 years (-15% per year).

Earnings vs Market: ACL's earnings are forecast to decline over the next 3 years (-15% per year).

High Growth Earnings: ACL's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ACL's revenue is expected to decline over the next 3 years (-2.1% per year).

High Growth Revenue: ACL's revenue is forecast to decline over the next 3 years (-2.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ACL's Return on Equity is forecast to be low in 3 years time (19.9%).


Past Performance

How has Australian Clinical Labs performed over the past 5 years?

60.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACL has high quality earnings.

Growing Profit Margin: ACL's current net profit margins (9.3%) are higher than last year (8.4%).


Past Earnings Growth Analysis

Earnings Trend: ACL's earnings have grown significantly by 60.3% per year over the past 5 years.

Accelerating Growth: ACL's earnings growth over the past year (46.3%) is below its 5-year average (60.3% per year).

Earnings vs Industry: ACL earnings growth over the past year (46.3%) underperformed the Healthcare industry 61.3%.


Return on Equity

High ROE: Whilst ACL's Return on Equity (73.72%) is outstanding, this metric is skewed due to their high level of debt.


Financial Health

How is Australian Clinical Labs's financial position?


Financial Position Analysis

Short Term Liabilities: ACL's short term assets (A$117.2M) do not cover its short term liabilities (A$166.2M).

Long Term Liabilities: ACL's short term assets (A$117.2M) do not cover its long term liabilities (A$226.6M).


Debt to Equity History and Analysis

Debt Level: ACL's debt to equity ratio (121.3%) is considered high.

Reducing Debt: Insufficient data to determine if ACL's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: ACL's debt is well covered by operating cash flow (154.9%).

Interest Coverage: ACL's interest payments on its debt are well covered by EBIT (8.5x coverage).


Balance Sheet


Dividend

What is Australian Clinical Labs's current dividend yield, its reliability and sustainability?

4.69%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ACL is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Melinda McGrath

0.83

Tenure

AU$2,384,811

Compensation

Ms. Melinda McGrath is Chief Executive Officer and Executive Director at Australian Clinical Labs Limited since December 19, 2020. She served as Chief Executive Officer and Executive Director at Clinical L...


CEO Compensation Analysis

Compensation vs Market: Melinda's total compensation ($USD1.79M) is above average for companies of similar size in the Australian market ($USD973.44K).

Compensation vs Earnings: Melinda's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ACL's management team is seasoned and experienced (6.8 years average tenure).


Board Members

Experienced Board: ACL's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: ACL only recently listed within the past 12 months.


Top Shareholders

Company Information

Australian Clinical Labs Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Australian Clinical Labs Limited
  • Ticker: ACL
  • Exchange: ASX
  • Founded: 2020
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$865.868m
  • Shares outstanding: 201.83m
  • Website: https://www.clinicallabs.com.au

Number of Employees


Location

  • Australian Clinical Labs Limited
  • 1868-1892 Dandenong Road
  • Clayton
  • Victoria
  • 3168
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/22 15:39
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.